CureSign
Monitoring Cancer Treatment Efficacy
Health Tech & Life Sciences
Non Active, Feb 2023 ceased to operate
Company Overview
Snapshot
Founded in February 2019 by Yakir Rottenberg, CureSign operated with 1–10 employees. The company secured funding across one round from two investors, with Peregrine Ventures participating. CureSign ceased operations in February 2023.
Business overview
CureSign was a medical device company focused on revolutionizing cancer treatment efficacy monitoring. Its core technology integrated sensors with advanced signal processing and big data tools to enable clinical teams to tailor patient-specific treatments. The company operated within the Health Tech & Life Sciences sector, specifically targeting oncology and medical device markets.
Company Intelligence Q&A
- What was CureSign's primary focus?
- CureSign focused on developing medical devices to monitor the efficacy of cancer treatments, aiming to enable personalized patient care through sensor integration, signal processing, and big data analytics.
- When was CureSign founded?
- CureSign was founded in February 2019.
- Who was a key founder of CureSign?
- Yakir Rottenberg was a co-founder, inventor, and medical director at CureSign.
- What was the operational status of CureSign?
- CureSign ceased to operate in February 2023.
- Which investors participated in CureSign's funding round?
- In February 2020, CureSign received funding from Peregrine Ventures and Nacre Capital.